Drug Profile
Research programme: cell cycle inhibitors - Cyclacel Pharmaceuticals
Alternative Names: Anti-HIV therapeutics research programme - Cyclacel Pharmaceuticals; Research programme: anti-HIV therapeutics - Cyclacel PharmaceuticalsLatest Information Update: 14 Jul 2014
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended HIV infections
Most Recent Events
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 26 May 2005 This programme is still in active development
- 13 Jul 2004 Preclinical trials in HIV infections treatment in United Kingdom (unspecified route)